# Mobile Technology for Reducing and Preventing Adolescent Suicide

> **NIH NIH R43** · OUI THERAPEUTICS, INC · 2021 · $398,984

## Abstract

ABSTRACT
Suicide is a top two cause of death in the US for adolescents and suicide rates among youth have steadily
increased. Despite this, there is a paucity of research on mobile technology designed to reduce suicide
attempts among youth. In this Phase I SBIR application Oui Therapeutics, LLC proposes a project to: 1) Create
a beta version of Aviva-Y for youth (ages 13 - 17); and 2) to test the feasibility and acceptability of the beta
version of Aviva-Y in a single-group, open-label trial. Successful execution of the goals of this Phase I project
will generate a version of Aviva-Y that is ready to be tested for efficacy with stabilized patients in a clinical trial.
In the long term, this project will have a beneficial impact on the field of youth suicide prevention through the
development of mobile technology designed to advance the delivery and dissemination of effective
interventions.

## Key facts

- **NIH application ID:** 10154817
- **Project number:** 1R43MH125691-01
- **Recipient organization:** OUI THERAPEUTICS, INC
- **Principal Investigator:** Seth Feuerstein
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $398,984
- **Award type:** 1
- **Project period:** 2021-02-15 → 2022-08-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10154817

## Citation

> US National Institutes of Health, RePORTER application 10154817, Mobile Technology for Reducing and Preventing Adolescent Suicide (1R43MH125691-01). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10154817. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*